Abstract
The purpose of this summary is to explain key findings from a study that included people with schizophrenia, as described in two separate articles (see the ‘Further Information’ section for more details).
The study compared a new formulation of aripiprazole, given as an injection once every 2 months, with a once‑monthly injection of aripiprazole.
Footnotes
Acknowledgements
Writing and editorial support for this summary was provided by Lyndal Staples, assisted by her colleagues at Cambridge – a Prime Global Agency (Knutsford, UK), and funded by Otsuka Pharmaceutical Development & Commercialization Inc. and H. Lundbeck A/S.